Glycaemic and cardiovascular efficacy of liraglutide in prediabetic patients with end-stage renal disease
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 07 Sep 2015
Price : $35 *
At a glance
- Drugs Liraglutide (Primary)
- Indications Prediabetic state; Renal failure
- Focus Therapeutic Use
- Acronyms The LiRA2 study
- 31 Aug 2018 Biomarkers information updated
- 21 Aug 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 04 May 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.